TRAPANI, DARIO
TRAPANI, DARIO
Dipartimento di Oncologia ed Emato-Oncologia
Advancing oncology innovation under persistent constraints
2026 D. Trapani, G. Curigliano
Invasive lobular and ductal breast cancers: a systematic review and metanalysis in association with BRCA1/2 mutation status
2026 G. Corso, C. Andreon, C. La Vecchia, E.I. Bottazzoli, G. Abruzzese, K. Favilla, O. Citterio, E. Spoldi, S. Di Silvestre, A.M. De Scalzi, A. Polizzi, E. Meduri, D. Trapani, L. Nicosia, F. Pesapane, D. Bossi, E. Brogi, S. Shen, R. Mukhtar, C. Criscitiello, P. Veronesi, S. Gandini, F. Magnoni, G. Curigliano
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer
2026 F. Lynce, C. Valenza, S.M. Niman, F. Bertucci, M. Kai, S. Ryan, E. Troll, R.M. Layman, K.A. Fanucci, A. Giordano, A. Nasrazadani, F. Nakhlis, J. Bellon, L. Warren, C. Block, S. Schumer, A. Lucci, S. Krishnamurthy, D. Trapani, F. Lerebours, F. Dalenc, C. Levy, T. Petit, M. Leheurteur, T. Bachelot, O. Tredan, J.M. Ribeiro, B. Pistilli, P. Zagami, S. Ladoire, L. Lopez Almeida, C. Zemmour, L.A. Carey, S.M. Tolaney, V. Valero, G. Curigliano, M.M. Regan, A. Goncalves, W.A. Woodward
Genomic landscape, immune microenvironment and survival in male versus female breast cancer
2026 D. Trapani, S.K. Deshmukh, T. Samec, S. Wu, J. Xiu, P. Walker, D.L. Abravanel, P. Advani, P.M. Spanheimer, N.U. Lin, G. Curigliano, S.L. Graff, M. Lustberg, G.W. Sledge, S.M. Tolaney, J.P. Leone
Impact of breast cancer on sexuality and psycho-physical wellbeing: Survey analysis
2026 P. Zagami, B.T. Salimbeni, E.P. Preti, A. Esposito, A. Marra, D. Trapani, E. Munzone, M. Mazza, S. Martella, I. Durosini, S. Perazzo, R. Marsicano, P.P. Maria Berton Giachetti, G. Curigliano, C. Criscitiello, G. Pravettoni
Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions
2026 J. Iranzo, E. Giordano, R.M. Marsicano, D. Trapani, A. Marra, C. Belli, P. Zagami, P.P.M. Berton Giachetti, E. Ferraro, I. Minchella, E. Crimini, G. Curigliano
A machine learning assay to predict disease recurrence in hormone receptor-positive breast cancer
2026 L. Boscolo Bielo, D. Trapani, P. Razavi, S. Chandarlapaty, Y. Zhan, G. Curigliano
Metastasis-directed thermal ablation in patients with metastatic breast cancer and visceral oligoprogression or oligopersistence: a cohort study
2026 N. Bianco, C. Valenza, M. Milano, R. Multinu, E. Battaiotto, M. Cavallone, G. Malvezzi, D. Trapani, P. Della Vigna, G. Bonomo, G.M. Varano, D. Maiettini, M.G. Pitoni, C. Sangalli, E. Munzone, G. Curigliano, M.A. Colleoni, F. Orsi
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study
2026 C. Valenza, Y. Zheng, M. Milano, D. Trapani, E. Giordano, L. Guidi, P.P.M. Berton Giachetti, L. Boldrini, G. Castellano, J. Katrini, B. Malagutti, G. Antonarelli, F. Conforti, E. Pagan, V. Bagnardi, G.J. Kirkner, C. Sangalli, K.E. Dibble, M. Colleoni, M.M. Regan, E. Munzone, G. Curigliano, A.H. Partridge
Extendeond Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients
2026 C. Valenza, Y. Zheng, M. Milano, P.P.M. Berton Giachetti, D. Trapani, E. Giordano, L. Guidi, L. Boldrini, G. Castellano, J. Katrini, B. Malagutti, G. Antonarelli, J.D. Etessami, N. Bianco, F. Conforti, G.J. Kirkner, C. Sangalli, K.E. Dibble, N. Fusco, M. Colleoni, M.M. Regan, E. Munzone, G. Curigliano, A.H. Partridge
Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study
2026 C. Valenza, J.D. Etessami, M. Milano, N. Papadopoulos, M. Alvino, G. Antonarelli, N. Bianco, C. Sangalli, D. Trapani, G. Pravettoni, E. Omodeo Salè, R. Passerini, M. Colleoni, E. Munzone, G. Curigliano
Do all patients with early breast cancer meeting the NATALEE criteria benefit from adjuvant ribociclib?
2025 C. Valenza, D. Trapani, G. Curigliano
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
2025 P.P.M. Berton Giachetti, S. Morganti, S. Gandini, F. Giudici, A. Marra, E. Nicolò, E. Zattarin, C. Corti, L. Boldrini, A. Verrazzo, C. Sposetti, M.G. Razeti, A. Carnevale Schianca, R. Scafetta, B. Taurelli Salimbeni, A. Esposito, P. Zagami, D. Trapani, B. Malagutti, R. Caputo, C. Vernieri, E. Munzone, S. Scagnoli, A. Botticelli, M. Lambertini, M. Giuliano, M. De Laurentiis, G. Viale, G. Bianchini, G. Curigliano, C. De Angelis, C. Criscitiello
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology
2025 F. Giugliano, E. Giordano, L. Gilardi, B.T. Salimbeni, P. Zagami, A. Esposito, A. Marra, D. Trapani, P.P.M. Berton Giachetti, B. Malagutti, T. Henry, D. Deandreis, G. Curigliano, F. Ceci, C. Criscitiello
Current controversies in the use of Oncotype DX in early breast cancer
2025 P.P.M. Berton Giachetti, A.C. Schianca, D. Trapani, A. Marra, A. Toss, C. Marchiò, M.V. Dieci, O.D. Gentilini, C. Criscitiello, K. Kalinsky, J.A. Sparano, G. Curigliano
Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy
2025 D. Izzo, L. Ascione, L. Guidi, R.M. Marsicano, C. Koukoutzeli, D. Trapani, G. Curigliano
The pathologic and genomic evolution of primary malignant phyllodes tumors of the breast: retrospective cohort study and case-control genomic analysis
2025 C. Valenza, D. Trapani, F.M. Porta, E. Olmeda, A. Gaeta, L. Boscolo Bielo, F. Conversano, T.M. De Pas, G. Castellano, C. Santoro, E. Battaiotto, E. Mane, S. Coppola, F. Conforti, D. Mattar, S. Gandini, P. Veronesi, E. Guerini Rocco, E. Pennacchioli, G. Curigliano
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)
2025 N.I. Cherny, S.F. Oosting, U. Dafni, N.J. Latino, M. Galotti, P. Zygoura, G. Dimopoulou, T. Amaral, J. Barriuso, A. Calles, B. Kiesewetter, C. Gomez-Roca, B. Gyawali, M. Piccart, A. Passaro, F. Roitberg, N. Tarazona, D. Trapani, G. Curigliano, R. Wester, G. Zarkavelis, C. Zielinski, E.G.E. De Vries
Circulating tumor DNA: a biomarker for oncology drug development in phase I clinical trials?
2025 R. Asnaghi, R.M. Marsicano, V. Fuorivia, G. Malvezzi, J.D. Etessami, D. Izzo, C. Valenza, G. Curigliano, D. Trapani
ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update
2025 N.I. Cherny, D. Trapani, M. Galotti, M. Saar, G. Bricalli, F. Roitberg, B. Gyawali, G. Curigliano, J. Blay, K. Meier, N.J. Latino, E.G.E. De Vries